LENZ
LENZ Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.30
+0.92%Year over year
Reported trailing growth
- Revenue
- +329.5%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +21.5%
- EBITDA
- +23.6%
- EPS
- +24.7%
Three-year CAGR
- Revenue
- +8.4%
- EBITDA
- -63.6%
- EBIT
- -55.5%
- Net income
- -65.0%
- EPS
- -21.8%
- Free cash flow
- -16.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026